Drug Profile
Nitroxylated albumin/chemotherapeutic - SynZyme Technologies
Alternative Names: VACNO®/chemotherapeutic - SynZyme Technologies; VAXOLLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator SynZyme Technologies
- Class Albumins; Nitrogen oxides
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral) (Synzyme Technologies, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Aug 2016 Nitroxylated albumin/chemotherapeutic - SynZyme Technologies is available for licensing -http://www.synzyme.com/gallery.html